{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.22","upperLimit":"4.12","value":"4.05"},{"groupId":"OG001","lowerLimit":"2.02","upperLimit":"24.00","value":"4.00"},{"groupId":"OG002","lowerLimit":"4.00","upperLimit":"24.00","value":"23.83"},{"groupId":"OG003","lowerLimit":"1.00","upperLimit":"7.83","value":"5.79"},{"groupId":"OG004","lowerLimit":"2.00","upperLimit":"22.55","value":"4.02"},{"groupId":"OG005","lowerLimit":"2.03","upperLimit":"4.12","value":"3.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.13","upperLimit":"4.00","value":"2.23"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"2.12","value":"2.00"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"1.08","value":"1.00"},{"groupId":"OG003","lowerLimit":"0.00","upperLimit":"7.50","value":"3.00"},{"groupId":"OG004","lowerLimit":"2.00","upperLimit":"4.00","value":"2.29"},{"groupId":"OG005","lowerLimit":"0.00","upperLimit":"2.07","value":"1.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"description":"Time to reach the maximum plasma concentration (Tmax) is presented.","dispersionType":"Full Range","groups":[{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose level of 100 mg until MTD or MED achieved.","id":"OG000","title":"Phase 1: FT-2102 100 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG001","title":"Phase 1: FT-2102 150 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose levels of 300 mg until MTD or MED achieved.","id":"OG002","title":"Phase 1: FT-2102 300 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG003","title":"Phase 1: FT-2102 150 mg BID (Single Agent)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\\^2) orally QD in 28-day cycles at dose levels of 150 mg until MTD or MED achieved","id":"OG004","title":"Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\\^2) orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG005","title":"Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy)"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set included those participants for whom it was possible to calculate at least 1 primary PK parameter and who had no major protocol deviations thought to influence the absorption, distribution, metabolism, and excretion of the FT-2102. Here, number anaylzed (n) = participants with available data for specific timepoints.","reportingStatus":"POSTED","timeFrame":"Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)","title":"Phase 1: Time to Maximum Plasma Concentration (Tmax) for FT-2102","type":"SECONDARY","unitOfMeasure":"hour"}